With multiple recent approvals of biologics to treat psoriasis Cosentyx (secukinumab, Novartis AG), Ilumya (tildrakizumab-asmn, Sun Pharmaceutical Industries Ltd.), Taltz (ixekizumab, Eli Lilly and Co.) and others companies are turning to topical treatments to capture the estimated 80 percent to 90 percent of psoriasis patients with mild to moderate disease where cheaper topical medications are more appropriate.